fitomega m8 (paziņots 2012.) cits, šķīdums
alfa omega s.r.l. - cits, Šķīdums
drenature (paziņots 2012.) šķidrums
new syform s.r.l. - šķidrums
repein (paziņots 2012.) cits, apvalkota tablete
evalar a/s - cits, apvalkota tablete
program 2 colo-vada plus (paziņots 2012.) cits, tabletes, kapsulas
rbc life sciences, inc. - cits, tabletes, kapsulas
fitomega dis 15 (paziņots 2011.) cits, šķīdums
alfa omega s.r.l. - cits, Šķīdums
fitomega cat 3 (paziņots 2010.) cits, šķīdums
alfa omega s.r.l. - cits, Šķīdums
sumamed 500 mg apvalkotās tabletes
teva b.v., netherlands - azitromicīns - apvalkotā tablete - 500 mg
azibiot 500 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - azitromicīns - apvalkotā tablete - 500 mg
locametz
novartis europharm limited - gozetotide - radionuklīdu attēlveidošana - diagnostikas radiofarmaceitiskie preparāti - Šīs zāles ir paredzētas tikai diagnostikas vajadzībām. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
glofix® skin boost (2023.) kapsula
kapsula